	2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PRESS	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	3.99	12.42	14.14	10.04	9.69	6.28	9.72	1.96	1.82
Cost of Operating Revenue	0.89	2.03	2.37	2.07	2.02	3.62	5.22	5.75	-0.50
Gross Profit	3.09	10.40	11.78	7.97	7.67	2.66	4.51	-3.79	2.32
Gross Margin	77.6	83.7	83.3	79.4	79.2	42.4	46.3	-192.9	127.8
Total Operating Expenses	3.53	9.40	10.96	7.29	7.54	11.34	12.91	10.64	1.18
Operating Profit	0.46	3.02	3.18	2.75	2.15	-5.06	-3.18	-8.67	0.63
Operating Margin	11.5	24.3	22.5	27.4	22.2	-80.7	-32.7	-441.7	34.8
Financing Income/(Expense) - Net	-0.20	-1.48	-1.84	-2.19	-2.35	-5.89	-5.75	-4.07	-0.78
Profit before Taxes	0.32	1.10	1.34	0.59	0.23	-10.26	-8.83	-12.63	0.01
Income Taxes	0.29	0.41	0.33	0.14	0.09	0.18	-0.22	0.66	-0.09
Profit after Tax	0.03	0.70	1.00	0.45	0.09	-6.48	-2.32	-4.77	0.11
PAT Margin	0.7	5.6	7.1	4.5	0.9	-103.3	-23.8	-243.2	6.0
EPS - Basic - ex Extraordinary Items	0.05	1.10	1.59	0.71	0.14	-10.27	-3.67	-7.56	0.15
EPS - Diluted - ex Extraordinary Items	0.05	1.10	1.59	0.71	0.14	-10.27	-3.67	-7.56	0.15
EBIT	0.46	3.02	3.18	2.75	2.15	-5.06	-3.18	-8.67	0.63
EBITDA	1.03	3.73	4.37	4.00	3.47	-2.39	1.31	-4.26	1.86
EBITDA Margin	25.9	30.1	30.9	39.8	35.8	-38.1	13.5	-216.8	102.5

Balance Sheet

Abridged

Understanding Balance Sheet

Vanta Bioscience Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	R 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PRESS	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	0.47	8.98	17.05	19.85	19.94	14.50	15.24	17.16	15.36	14.13
Long-Term Investments	-	-	-	-	-	-	-	-	-	0.88
Property Plant & Equipment - Net	12.95	14.97	16.74	22.90	34.86	37.32	33.23	28.41	23.96	9.68
Total Non-Current Assets	13.28	20.18	21.95	28.73	49.69	66.91	69.47	68.24	70.52	51.97
Total Assets	13.75	29.16	39.00	48.57	69.63	81.40	84.71	85.40	85.88	66.10
Total Current Liabilities	0.10	2.37	3.20	9.87	14.84	17.76	17.75	22.88	26.56	11.82
Long Term Debt	7.50	9.98	12.17	13.65	27.84	33.52	47.07	48.80	54.13	31.21
Total Non-Current Liabilities	7.50	10.21	12.57	14.24	28.56	34.30	48.03	49.55	55.53	33.11
Total Liabilities	7.60	12.57	15.77	24.12	43.40	52.06	65.78	72.42	82.10	44.93
Total Shareholders' Equity	6.15	16.59	22.25	23.47	23.92	24.01	17.51	15.20	10.42	21.18
Minority Interest	-	-	0.98	0.99	2.31	5.34	1.41	-2.23	-6.64	-
Total Equity	6.15	16.59	23.23	24.46	26.23	29.34	18.93	12.97	3.78	21.18
Total Liabilities & Equity	13.75	29.16	39.00	48.57	69.63	81.40	84.71	85.40	85.88	66.10

Cash Flow

Abridged

Understanding Cash Flow Statement

Vanta Bioscience Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2017 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	-	1.81	2.53	1.82	1.54	-7.59	-4.37	-8.21	1.24
Working Capital - Increase/(Decrease)	0.07	-4.54	-2.14	3.01	1.39	1.08	1.31	1.74	-7.24
Net CF from Operating Activities	0.07	-2.73	0.39	4.83	2.93	-6.51	-3.06	-6.48	-6.00
Capital Expenditures - Net	12.95	2.48	7.35	22.19	17.18	5.91	3.31	6.69	6.87
Net CF from Investing Activities	-13.28	-5.50	-7.35	-22.19	-17.18	-5.91	-3.31	-6.69	-6.87
Stock - Issuance/(Retirement) - Net	6.15	8.96	-	1.32	2.98	-	2.65	4.10	4.00
Debt - LT & ST - Issuance/(Retirement) - Total	7.51	2.67	4.12	18.60	8.90	12.29	3.79	9.13	7.61
Net Cash Flow from Financing Activities	13.66	11.63	4.12	19.92	11.88	12.29	6.44	13.23	12.86
Free Cash Flow to Equity	-5.37	-2.53	-2.84	1.24	-5.35	-0.13	-2.59	-4.04	-5.26
Free Operating CF net dividend	-12.88	-5.20	-6.96	-17.36	-14.25	-35.20	-6.47	-13.17	-12.87
Free Operating CF	-12.88	-5.20	-6.96	-17.36	-14.25	-35.20	-6.47	-13.17	-12.87

Business Segment Analysis

FY End:

Mar 21

Vanta Bioscience Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Preclinical Contract Research (100.0%)₹ 22.19 Cr

Revenue / Sales

Preclinical Contract Research (100.0%)₹ 10.04 Cr

Assets

Preclinical Contract Research (100.0%)₹ 69.63 Cr

Operating Income

Preclinical Contract Research (100.0%)₹ 2.75 Cr

Regional Segment Analysis

Vanta Bioscience Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Vanta Bioscience Ltd.

Historical Segment Analysis

Track how Vanta Bioscience Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2019 Mar 31	2020 Mar 31	2021 Mar 31

Preclinical Contract Research	2	7	22

Frequently Asked Questions

What is the revenue of Vanta Bioscience Ltd.?

The latest trailing twelve month revenue of Vanta Bioscience Ltd. is ₹ 1.82 Cr, reflecting a 1-year growth of -7.49% and a 3-year CAGR of -33.85%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Vanta Bioscience Ltd.?

The latest trailing twelve month net profit (PAT) of Vanta Bioscience Ltd. is ₹ 0.11 Cr. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Vanta Bioscience Ltd.?

The trailing twelve month EBITDA of Vanta Bioscience Ltd. is approximately ₹ 0.63 Cr (based on an operating margin of 34.77%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Vanta Bioscience Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Vanta Bioscience Ltd. is 0.15. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Vanta Bioscience Ltd.?

The debt-to-equity ratio of Vanta Bioscience Ltd. stands at 1.80. The interest coverage ratio is 0.81x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Vanta Bioscience Ltd.?

The estimated book value per share of Vanta Bioscience Ltd. is 29.77 (derived from a P/B ratio of 0.85 and market price of ₹ 25.29), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Vanta Bioscience Ltd.?

The trailing twelve month operating cash flow of Vanta Bioscience Ltd. is ₹ -6.00 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Vanta Bioscience Ltd. report consolidated or standalone financials?

Vanta Bioscience Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.